argenx SE/$ARGX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Ticker
$ARGX
Sector
Primary listing
Employees
1,599
Headquarters
Website
argenx SE Metrics
BasicAdvanced
$50B
35.08
$23.27
0.04
-
Price and volume
Market cap
$50B
Beta
0.04
52-week high
$934.62
52-week low
$510.06
Average daily volume
351K
Financial strength
Total debt to equity
0.708
Interest coverage (TTM)
223.39%
Profitability
EBITDA (TTM)
721.41
Gross margin (TTM)
54.84%
Net profit margin (TTM)
41.63%
Operating margin (TTM)
21.63%
Effective tax rate (TTM)
-59.41%
Revenue per employee (TTM)
$2,300,000
Management effectiveness
Valuation
Price to earnings (TTM)
35.081
Price to revenue (TTM)
13.518
Price to book
6.98
Price to tangible book (TTM)
7.24
Growth
Revenue change (TTM)
92.98%
Earnings per share change (TTM)
-3,537.00%
3-year revenue growth (CAGR)
134.49%
10-year revenue growth (CAGR)
79.42%
3-year earnings per share growth (CAGR)
11.00%
argenx SE News
AllArticlesVideos
This year's biotech laggards primed for 2026 recovery, says Goldman Sachs' Richter
CNBC Television·1 month ago
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga·1 month ago
Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus
Benzinga·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for argenx SE stock?
argenx SE (ARGX) has a market cap of $50B as of January 22, 2026.
What is the P/E ratio for argenx SE stock?
The price to earnings (P/E) ratio for argenx SE (ARGX) stock is 35.08 as of January 22, 2026.
Does argenx SE stock pay dividends?
No, argenx SE (ARGX) stock does not pay dividends to its shareholders as of January 22, 2026.
When is the next argenx SE dividend payment date?
argenx SE (ARGX) stock does not pay dividends to its shareholders.
What is the beta indicator for argenx SE?
argenx SE (ARGX) has a beta rating of 0.04. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.